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Abstract
The rapid evolution of novel, costly therapies for neuroendocrine neoplasia (NEN) warrants formal high-quality cost-effective-
ness evaluation. Costs of individual investigations and therapies are high; and examples are presented. We aimed to review the
last ten years of standalone health economic evaluations in NEN. Comparing to published standards, EMBASE, Cochrane
library, Database of Abstracts of Reviews of Effects (DARE), NHS Economic Evaluation Database and the Health
Technology Assessment (HTA) Database were searched for health economic evaluations (HEEs) in NEN published between
2010 and October 2019. Of 12 economic evaluations, 11 considered exclusively pharmacological treatment (3 studies of SSAs, 7
studies of sunitinib, everolimus and/or 177Lu-DOTATATE and 1 study of telotristat ethyl) and 1 compared surgery with
intraarterial therapy. 7 studies of pharmacological treatment had placebo or best supportive care as the only comparator. There
remains a paucity of economic evaluations in NEN with the majority industry funded. Most HEEs reviewed did not meet
published health economic criteria used to assess quality. Lack of cost data collected from patient populations remains a
significant factor in HEEs where clinical expert opinion is still often substituted. Further research utilizing high-quality effec-
tiveness data and rigorous applied health economic analysis is needed.
Keywords Neuroendocrine neoplasia . Health economic evaluation . Neuroendocrine tumour . Carcinoid tumour . Carcinoid
syndrome
1 Introduction
Neuroendocrine neoplasms (NEN) occur throughout the
body, the most common sites being pulmonary and digestive.
NEN range from well-differentiated neuroendocrine tumours
(NET) to poorly-differentiated carcinomas termed neuroendo-
crine carcinomas (NEC) [2]. They have varying growth char-
acteristics: low grade and indolent to high grade and
aggressive. NEN arising in the gastrointestinal tract are termed
gastroenteropancreatic neuroendocrine tumours (GEP NETs).
The move from International Classification of Diseases
(ICD) 10 to ICD-0-3 resulted in a more accurate classification
of NEN. A further update to grade and stage classification in
2018 gave more reliability across users and systems [36]. As a
result of these improvements the histological nomenclature
and classification of NEN is starting to more accurately reflect
the true incidence and prevalence of NEN and its subsets.
NEN incidence is rising [12, 19]. NEN incidence in
England is 9.37 per 100,000 according to the UK’s National
Cancer Registration and Analysis Service(NCRAS) [62].
Rising incidence of these types of tumour is as yet unex-
plained but be real, or may relate to increased diagnosis [22]
or improved classification systems. In 2017, NEN prevalence
in England was 48 per 100,000 [62]. This is greater than most
other upper gastrointestinal cancers (e.g. the incidence of gas-
tric cancer stood at 29.6 per 100,000 in 2010) [6]. In the
United States, annual age-adjusted incidence of NETs was
1.09 per 100,000 in 1973 and increased to 6.98 per 100,000
by 2012[12]. Increasing incidence of NEN has also been ob-
served in Spain [18], France [33] and Italy[5].
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The heterogeneous clinical presentation and biology of NEN
with often vague abdominal symptoms can present a challenge in
diagnosis and management. Delayed diagnosis, which increases
health care costs in a range of diseases [17, 24, 39], is likely to be
factor in NEN. Patients with NEN are often initially
misdiagnosed or can experience delay to diagnosis of up to five
years [4]. High resource utilisation before diagnosis [53] and an
expensive diagnostic process [23] contribute to increased overall
costs in this phase. An advanced stage at diagnosis confers sig-
nificantly poorer outcomes of NENs compared with non-NENs
at the same anatomical site [19].
Treatment options comprise surgery, targeted therapies,
peptide receptor radionuclide therapy (PRRT), trans-arterial
chemoembolization (TACE), thermal ablation of liver lesions
in the form of radiofrequency ablation (RFA) or microwave
ablation (MWA), chemotherapy and liver transplant. The
mainstay of treatment in GEP-NETs is long term long-acting
somatostatin analogues [60]. Treatment in NEN is also long-
term with surgery for advanced GEP-NETs unlikely to be
curative [60]. There is a lack of evidence on the best way to
investigate and diagnose a NEN in the face of innovative,
costly investigation and treatment. Therapy for NEN is report-
ed by patients to vary internationally, and there has been crit-
icism about disparities in access to treatments across countries
[35]. A multidisciplinary team approach is important for the
optimal treatment of patients with GEP NETs [30, 59].
Thetotalcostofmanagingillness inNENisanimportant figure
for healthcare commissioners to achieve an adequate and fair dis-
tribution of limited resources across healthcare systems. Some
studies have estimated the cost using combinations of physician
surveys [8] and registry linkage [23, 34] but results are not neces-
sarily applicable to the UK due to differences in pricing of treat-
ments, health systemsandeconomies.Cost of care in cancer in the
UK has been calculated [32]. Decisions about which costs fall
within and outside the scope and perspective depend on the
decision-maker and can have a significant impact on the resulting
cost of illness [25]. In termsof cost-effectiveness, quality-adjusted
life years (QALYs) are often the measure of health benefit pre-
ferred, and these require appropriate estimation of utility values
(QALYweights). The preferredmeasure of health-related quality
of life by the National Institute for Clinical Excellence (NICE) in
adults has been EQ-5D since 2008 [42].
Pharmaceutical pricing is the single largest factor impacting
the cost of care in the form of long acting somatostatin ana-
logues and targeted therapies [3, 23, 46]. A large registry-linked
study found the pharmaceutical cost burden formed 42% of the
yearly total cost of managing NEN [34]. In the maintenance
phase of illness (more than a year after diagnosis), per patient
costs in NEN were found to be triple of those in colon cancer
due primarily to pharmaceutical costs [23].
There is a high cost of biochemical testing of blood and
urine in NEN due to measurement of serum chromogranins
and urine 5-Hydroxyindoleacetic acid. Radiological
monitoring post-diagnosis and treatment for NEN is also cost-
ly (Table 1). Most patients will need computed tomography
(CT) at diagnosis with many additionally needing magnetic
resonance imaging (MRI) [16]. In stage 2–3 disease follow up
CT can be six monthly for up to five years, but in stage 4
disease radiological monitoring can be for many years longer.
Positron emission tomography (PET) scans are now common-
ly performed at diagnosis with many patients needing
fluorodeoxyglucose (FDG-PET) as well as Dotatate-PET to
establish “radiological grading” [57].
1.1 An overview of healthcare costs in England
(Table 1) [45]
Somatostatin analogue costs range between £800–£1000 per
month (pm). Targeted therapies such as everolimus or suniti-
nib cost £2000–3000 pm [45]. PRRT costs £40–50,000 per
patient with many patients now having multiple cycles to con-
trol disease burden (Kings Health Partners Business
Intelligence unit, personal communication). Chemotherapy
costs are mostly due to high-cost drugs, with chemotherapy
unit attendance contributing a much smaller part [45].
The most frequently used chemotherapy regimens are
Temozolamide with Capecitabine oral combination therapy
or single agent platinum-based intravenous treatment. In the
treatment of grade 2 metastatic NEN, temozolamide is esti-
mated to cost £1176 per 5 day cycle and capecitabine £120 per
14 day cycle [43]. For grade 3 NEN, a platinum-based intra-
venous regimen would cost £76.18 per cycle for carboplatin
and £30.89 for etoposide [44], in addition to the attendance
cost estimated at £130 per day on a chemotherapy unit [45].
Reimbursed costs for surgery and interventional radiology
treatments in England (Table 2) [45] HRG = Healthcare
Resource Group
Health economic evaluations (HEEs) are increasingly adopted
by the UK government to assess treatments [49]. HEEs have be-
comeanintegralpartof rationaldecisionmakinginhealthcareand
form a key part of health technology assessments (HTAs). NICE
requires for all new pharmaceuticals to have HEE and will often
commission HEEs where there is an absence of existing cost-
Table 1 Dotatate-PET scans are costed at £1800 in one London centre
(Nuclear Medicine Department, King’s College Hospital- personal com-
munication) with an average stage 4 disease patient requiring one or two
scans
Imaging modality Cost (£)
FDG PET 578
Dotatate PET 1800
Tektroyd 1273
Pre SIRT shunt scan (MAA) 963
Selective Internal Radiation Therapy (SIRT) techniques can also be utilized
which need aMacroaggregated Albumin (MAA) scan to be done beforehand
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effectiveness evidence. HEEs appear to have amajor influence in
NICE’s decision process; one research paper demonstrated the
economic calculation could predict 82% ofNICE decisions [11].
In HEE the following questions are posed: firstly whether a
treatment is worth doing compared with other things we could
do with the same resources, and secondly if these resources
should be spent in this way and not on something else [14] .
1.2 Types of health economic evaluation (Table 3)
2 Aim
The aim of the paper was to systematically review and criti-
cally evaluate standalone English-language literature on
health economics in NEN over the last decade. Previous re-
views [9, 21] found limited numbers of health economic eval-
uations. Novel therapeutics also justify a focus on more recent
evaluations.
3 Methods
A literature search was performed including EMBASE,
Cochrane library, Database of Abstracts of Reviews of
Effects (DARE), NHS Economic Evaluation Database and
the Health Technology Assessment (HTA) Database. The last
three were searched using the Centre for Reviews and
Dissemination (CRD) Database. A Preferred Reporting
Items for Systematic Reviews and Meta-Analyses
(PRISMA) flow diagram was generated. (Fig. 1).
Articles were searched by citation and abstract. Papers pub-
lished from 2010 to October 2019 in English were included.
We looked at treatment search terms, taking into account
terms used in previous reviews by Chau et al. [9] and
Grande et al. [21] (Table 4). See Appendix 1 for full search
strategy terms. Further literature, including grey literature, was
identified using a Google scholar search using the same terms.
Citation searching was performed to ensure completeness.
The following were excluded: papers which were not eco-
nomic evaluations or reviews of economic evaluations, papers
which did not relate to NEN, papers not in English and budget
impact studies. Cost of illness studies were excluded since
limiting analysis strictly to HEEs was considered optimal.
Initial screening for excluding the above categories was
conducted by a researcher. Subsequently, each paper was
reviewed by three experts. The reviewers agreed on the final
group of articles to be included in the review. If reviewers
disagreed, a majority decision was taken.
Data on the methods and results of studies were abstracted
into a standardised table by a researcher (BW) and checked by
an experienced health economist (TS). Studies were critically
appraised by TS using the CHEC list for trial-based economic
evaluations and the Philips checklist for model-based eco-
nomic evaluations [15, 47]. Results of data extraction were
analysed by all authors.
4 Results
EMBASE, Cochrane and CRD search yielded 1388 articles.
Google Scholar and citation tracking combined gave 145 re-
sults, making a total of 1533 articles. 22 articles were dupli-
cates leaving 1511. 1470 articles were excluded. 41 articles
were retrieved of which 29 were excluded making 12 total.
There were 6 papers and 6 abstracts included.
Table 3 The ICER or incremental cost-effectiveness ratio is the amount
of extra cost which will be incurred for a unit gain of health benefit
Health economic
evaluation
Description
Cost-minimisation
analysis (CMA)
Assumes there are no differences in the benefits
so only costs are considered
Cost-consequence
analysis (CCA)
Typically identifies multiple benefits and
presents these alongside costs
Cost-effectiveness
analysis (CEA)
Identifies a single benefit measure and reports the
incremental cost-effectiveness ratio (ICER)
Cost-utility analysis
(CUA)
A special case of CEA where the benefit is a
composite of health-related quality and
quantity of life utility measure e.g.,
quality-adjusted life years (QALYs)
Cost-benefit analysis
(CBA)
Identifies one or more benefits and assigns
monetary values to these benefits to be offset
against costs.
A QALY or quality-adjusted life year is equal to 1 year of life in perfect
health. QALYs can be calculated by estimating the years of life remaining
for a patient following a particular treatment or intervention and
weighting each year with a quality-of-life score (on a 0 to 1 scale)
Table 2 National Health Service healthcare resource group (HRG) codes
and tariff (in GB Pounds) covering the whole cost of each admission for
the procedure
Procedure HRG Tariff (£)
Orthotopic transplantation of whole liver GA15 80,000
Right hemihepatectomy NEC GA04 10,801
Pancreaticoduodenectomy NEC GA03 9263
Left pancreatectomy NEC GA05 8405
Right hemicolectomy FF32 5947
Small bowel resection FF21 6109
RFA to liver GA13 2141
Thermal ablation of single lesion of liver GA13 2141
Rev Endocr Metab Disord
Table 5a and b display the country of origin and funding
source for the studies. Table 6 displays the study characteris-
tics and Table 7 study results.
The Philips checklist [47] was applied to all economic
evaluations (Appendix 2). All studies clearly stated their de-
cision problem andmost studies clearly reported the scope and
perspective of their study, including the time horizon. Studies
generally did not present evidence for the structures of their
models, although most studies adopted similar structures
(health states for pre-progression, post-progression and death),
which likely arises as a result of the prominence of
progression-free survival as a key endpoint in RCTs.
A number of studies excluded relevant comparators with-
out justification (e.g., studies evaluating sunitinib but not
everolimus). Most studies did not describe their methods for
identifying data to inform model inputs and it was often un-
clear how relevant the utilities or QALYweights incorporated
within models were. Exploration of uncertainty was sporadic,
with parameter uncertainty most likely to be explored
(through one-way sensitivity analyses and probabilistic sensi-
tivity analysis), and most studies did not report internal and
external validation.
Results from economic evaluations are grouped by com-
parison of treatments. Of twelve economic evaluations, eleven
considered exclusively pharmacological treatment (three
studies of SSAs, seven studies of sunitinib, everolimus and/
or 177Lu-DOTATATE, one study of telotristat ethyl) and one
compared surgery with intraarterial therapy. Seven studies of
pharmacological treatment had placebo or best supportive
care as the only comparator.
5 Somatostatin analogues (SSAs)
Marty et al. [37] developed a decision tree model to perform a
cost-minimisation analysis of lanreotide (extended release for-
mulation; trade name Somatuline Autogel® or Somatuline
Depot®) versus octreotide (trade name Sandostatin LAR®).
The measure of benefit was a successful injection (as there is a
risk of clogging), and costs were estimated from French,
German and UK healthcare payer perspectives and reported
in 2010 Euros. The study found, through a combination of
longer administration times and higher risk of clogging with
octreotide, lanreotide to be cheaper per successful injection
(France €34.90, Germany €91.10, UK €142.90). The study
included only drug acquisition and administration costs, and
did not include costs of adverse events or any measure of
health benefit. The data source for administration time was a
study in which nurses were timed performing injections into
pads. The nurses were shown an instructional video on
Fig. 1 PRISMA flow chart of
search strategy
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injection preparation and administration for lanreotide prior to
administering lanreotide, whereas they were only provided
with printed instructions for octreotide. Prior to this they were
also given a demonstration and explanation of the features of
the lanreotide pre-filled syringe and were asked to describe its
most important characteristics.
Takemoto et al. [58] developed a three health state Markov
model to assess the costs and consequences of octreotide ver-
sus best supportive care (BSC) in patients with metastatic
midgut NET. The measure of benefit was progression-free
survival. Costs were estimated from the private payer perspec-
tive and reported in Brazilian real (BRL). The primary source
for effectiveness data was published data from the phase III
PROMID trial [52]. Subjects remained on treatment until
progression and resource use was estimated through published
data and input from clinical experts. They state that octreotide
is a clinically effective option to control tumour growth in
patients with metastatic midgut NET. The authors state that
since PROMID was not designed to evaluate OS they were
unable to calculate life years gained.
Ray et al. [50] developed a decision tree model to assess the
cost of treating unresectable, well-differentiated, advanced
GEP-NET patients over a 6-month time horizon after they
progress on octreotide. The stated basis is evidence of benefit
to patients from switching to lanreotide after octreotide prior
to modifying treatment class. There was no measure of health
benefit (i.e., cost-minimisation analysis). Drug acquisition/ad-
ministration, serious adverse event and patient management
Table 4 Search terms
Neuroendocrine tumour
terms
Treatment terms Health economics terms Study type terms
Neuroendocrine Tumo*
Neuroendocrine
Neoplasia
Carcinoid
tumo(u)r/syndrome
Octreotide
Angiopeptin
Alpha interferon (& similes)
Everolimus
Rapamycin
Sunitinib
Lutetium 177 (& similes)
Lanreotide
Sirolimus
Sunitinib or 177lu)
Chemotherapy
Radiotherapy
Ablation
Radioemboliz(s)ation
Artificial emboliz(s)ation
Surgery
Trans arterial
chemoemboliz(s)ation
Telotristat
Economics
Hospitalization & Hospitalization costs (& similes)
Cost of illness
Mortality
Ambulatory care
Work Disability
Health care cost (& similes)
Treatment pattern
Drug utilization (& similes)
Unmet needs
Quality of life
Health economic analysis
Health economics
Health care utilization
Resource utilisation (& similes)
Financial toxicity
Cost-effectiveness
Cost of disease/sickness/illness
Burden of disease/illness
Hospital/illness/sickness/health*/medical care cost
Drug cost
Cost of medical care/drug/healthcare (&
similes)/treatment(& similes)
Economic burden
Economic impact
Health services
Drug prescriptions
Direct cost
Intangible cost
Surg* cost
Payment
Pharmacoeconomic
Absenteeism
Illness/sick day
Sick leave
Work absen*
Retirement
Work/work day/time loss
Work incapability/ incapacity
Workers compensation
Registries
Observational studies
Review articles
Guidelines or consensus
pieces
Meta-analyses
Systematic reviews
Surveys
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costs were considered. Patients could utilize octreotide esca-
lation (30 mg every 3 weeks or 40 or 60 mg every 4 weeks),
OCT plus PRRT, OCT plus liver-directed therapy, everolimus
or lanreotide every 4 weeks. Costs were estimated from a US
insurance payer perspective and reported in US dollars.
Results were that lanreotide was found to be cost-saving ver-
sus alternatives when used post-octreotide. The authors state
that clinical appropriateness must be considered when
transitioning patients.
6 Everolimus, sunitinib and 177Lu-DOTATATE
Casciano et al. [7] developed a partitioned survival model to
conduct a cost-utility analysis of sunitinib versus everolimus
in patients with advanced, progressive pancreatic NET from a
US payer perspective. The measure of benefit was QALYs
and cost-effectiveness thresholds of $50,000 and $100,000/
QALY were considered. Data from two RCTs (A6181111,
RADIANT-3) were synthesised using the matching-adjusted
indirect comparison method and using individual patient data
from RADIANT-3[51, 65]. For PFS this was an anchored
comparison (with placebo control as a common comparator),
but for OS this was an unanchored comparison, because sig-
nificant treatment switching was observed after disease pro-
gression in the control arms, leading to confounding of OS
estimates. The study estimated that everolimus would im-
prove life expectancy and QALYs at an additional cost, with
an ICER of $41,702/QALY. The primary threat to the validity
of this study is the use of an unanchored indirect comparison
of OS from two studies, which requires assumptions which are
acknowledged to be generally very difficult to justify [48].
Chua et al. [10] developed a partitioned survival model to
conduct a cost-utility analysis of everolimus (with BSC) ver-
sus BSC alone in patients with advanced or metastatic NET of
GI or lung origin from a Canadian healthcare payer perspec-
tive (although described by the authors as a societal perspec-
tive). The measure of benefit was QALYs and a cost-
effectiveness threshold of CA$150,000 was considered.
Intention to treat data from RADIANT-4 [66] informed PFS
and OS estimates up to month 26, however after this point a
proportional hazards assumption for OS was imposed. Health
state utility values were estimated by mapping from FACT-G
measured in RADIANT-4 to EQ-5D values. The study esti-
mated that everolimus would improve life expectancy and
QALYs at an additional cost, with an ICER of CA$145,670/
QALY. The ICER was sensitive to the hazard ratio for long-
termOS and to the time horizon, suggesting that the economic
value is derived in significant part from extrapolation beyond
the trial evidence.
Mujica-Mota et al. [41] developed a partitioned survival
model to conduct a cost-utility analysis of sunitinib, everoli-
mus, and 177Lu-DOTATATE versus BSC in patients with
advanced unresectable or metastatic NET. The measure of
benefit was QALYs and costs were included from an NHS
and personal social services perspective. Four RCTs [51, 56,
65, 66] were used to estimate PFS and OS, however these
RCTs had heterogeneous patient populations. Sunitinib could
only be included when the population was limited to pancre-
atic NET, reflecting its licensed indication, and 177Lu-
DOTATATE could only be included when the population
was limited to gastrointestinal (midgut) NET. Ultimately three
versions of the model were constructed: for pancreatic NET
data from RADIANT-3 [65] and A6181111 [51] were com-
bined; for GI (midgut) NET data from RADIANT-4 [65] and
NETTER-1 [56] were combined; and for GI and lung NET
only data from RADIANT-4 was included. The study found
that everolimus was unlikely to be cost-effective in any of the
settings at its list price, sunitinib was likely to be cost-effective
in pancreatic NET, and 177Lu-DOTATATEwas unlikely to be
cost-effective in GI (midgut) NET. The main limitation of the
study is that indirect comparison was required for evidence
synthesis because all RCTs were placebo-controlled rather
than being head-to-head RCTs of active treatments.
Soares et al. [54], Walczak et al. [61], Johns et al. [26] and
Kansal et al. [28] developedmodels to conduct cost-utility and
cost-effectiveness analyses of sunitinib plus BSC versus pla-
cebo plus BSC in advanced unresectable or metastatic pancre-
atic NET. All four studies were supported by Pfizer. The mea-
sure of benefit was life years (LY) in Soares et al. [54] but was
QALYs in the other study abstracts. The cost-effectiveness
Table 5 Countries of
origin and funding
sources
a Country of origin
Country Number
United States 4
Brazil 1
Canada 1
France 1
Netherlands 1
Poland 1
Portugal 1
Scotland & Wales 1
United Kingdom 1
Total 12
b Funding source
Source Number
Novartis 2
IPSEN 2
Not stated 5
Lexicon 1
Publicly funded 1
Pfizer 1
Total 12
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threshold was not stated in Soares et al., but anecdotally
Portugal adopts a threshold of €30,000/QALY [67]. The
cost-effectiveness threshold was stated by Walczak et al.
[61] to be 99,543 PLN/QALY in Poland, and was stated by
Johns et al. [26] to be £50,000/QALY in the UK for end-of-
life treatments. Kansal et al. [28] did not state a cost-
effectiveness threshold. A single RCT (A6181111) was used
as the source of evidence in all studies. In Soares et al. [54] and
Johns et al. [26] OS was adjusted for treatment switching
using the rank-preserving structural failure time (RPSFT)
method.
Soares et al. [54] estimated a LY gain of 1.83 with an ICER
of €24,035/LY. When using ITT analysis (instead of RPSFT)
the ICER increased to €34,387/LY.Walczak et al. [61] did not
report costs and benefits separately but reported an ICER of
84,214 PLN/QALY (€20,441/QALY). Johns et al. [26] esti-
mated an ICER of £22,587/QALY. Kansal et al. [28] estimat-
ed an ICER of €52,401/QALY.
7 Telotristat ethyl
Joish et al. [27] developed a Markov model to conduct a cost-
utility analysis of telostristat ethyl added to octreotide (TE +
SSA) versus octreotide alone (SSA) in patients with carcinoid
syndrome diarrhoea (CSD). Costs were included from a third-
party US payer perspective and the measure of benefits was
QALYs. The cost-effectiveness threshold was $150,000/
QALY but thresholds of $300,000 and $450,000/QALY were
also argued to be relevant as CSD was argued to be an ultra-
orphan condition. Themodel included states for adequate con-
trol and inadequate control, as well as death. Patients in the
SSA arm could transition from adequate control to inadequate
control but patients in the TE + SSA arm could not. The key
source of effectiveness data was a multi-country RCT [29].
Utilities were estimated from a vignette study of ulcerative
colitis patients. A biomarker, u5-HIAA, was used as a surro-
gate outcome which was assumed to mediate a mortality ben-
efit. The study found that TE + SSA increased QALYs by
0.66 at an additional cost of $94,962 (ICER $142,545/
QALY). This was considered cost-effective at the thresholds
considered but these thresholds are higher than typically used
in US economic evaluations ($50,000 and $100,000/QALY).
The most significant threats to validity of results generated
from in this case was the assumption that ulcerative colitis
health state utility values elicited using vignettes are an appro-
priate proxy for CSD health states and the surrogate assump-
tion that the observed association between u5-HIAA and mor-
tality is a suitable basis for estimating the effect onmortality of
an intervention from its effect on u5-HIAA. It would instead
seem more appropriate to take existing measures of health-
related quality of life in this disease cohort, e.g., EORTC
QLQ-C30 in the TELESTAR study [29], and using a utilityT
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mapping algorithm [64] to estimate preference-based utility
values. This would narrow the gap in utility between adequate
and inadequate control patients.
8 Surgery and intra-arterial therapy
Spolverato et al. [55] developed a Markov model to conduct a
cost-utility analysis of hepatic resection (HR) versus
intraarterial therapy (IAT) for patients with NELM. Costs
were included from a US health care provider’s perspective
and the measure of benefits was QALYs. The cost-
effectiveness threshold was $50,000 per QALY. The only
health events incorporated in the model were retreatment
and death. The key sources of effectiveness data was a retro-
spective cohort study [38] of individuals undergoing treatment
for NELM by HR or IAT over a 25 year period at one of nine
US institutions. In the base case (57-year-old man with
metachronous symptomatic NELM involving <25% of liver
and no extrahepatic disease) HR was cost-effective versus
IAT, however other cases were identified where HR was not
cost-effective, e.g., when asymptomatic but with hepatic in-
volvement ≥25%. There was no accounting for confounding
in the primary evidence source (since IAT recipients were
more likely to have greater hepatic involvement and presence
of extrahepatic metastases), so the economic evaluation likely
overestimates the survival benefit from HR versus IAT and its
cost-effectiveness.
9 Discussion
It was stated in the review by Chau et al. [9] that “Although
the published literature in the area of NET is substantial, there
is a lack of treatment-specific and comparative economic and
outcomes research data associated with commonly used treat-
ments”. In a subsequent review in 2019 Grande et al. [21]
suggested “further economic evaluations are required to in-
form healthcare decision-making”. Our review demonstrates
health economic literature in NEN which fulfils quality
criteria for HEEs is still scarce.
Despite there being more HEE in the literature than in the
previous decade there remains a paucity of economic evalua-
tions, the majority of which are partly or wholly industry
funded. The lack of cost data collected from relevant patient
population remains the main weakness of existing evidence
from HEEs. Another limitation relates to the lack of data on
medium to long term survival outcomes and therefore the
need to rely on clinical expert opinion for predicting those
outcomes beyond one or two years after the start of targeted
therapies, particularly in gastrointestinal NEN [41].
The long-term treatment of NEN is costly due in the most
part to pharmaceuticals. In one cost analysis, the long term
follow-up of NEN was significantly more costly when com-
pared to colon cancer. The authors demonstrated that almost
all of this increased cost was due to maintaining drug treat-
ments such as SSAs [23]. Due to heterogeneity of treatment
pathways in NEN it is difficult to calculate accurate continu-
ing costs for the whole cohort. We would expect further liter-
ature to emerge on the cost-effectiveness of lutetium
treatment.
A problem frequently observed in RCTs of anti-cancer
therapies is that patients in the control arm are allowed to
switch to the study drug following disease progression [31].
This leads to confounding in post-progression endpoints, for
example overall survival, and renders estimates of these end-
points unsuitable for inclusion in economic models without
some form of adjustment. The rank-preserving structural fail-
ure time (RPSFT) method was used in three included studies
[26, 41, 54] to adjust for this confounding, but this method
typically assumes that the treatment effect received by
switchers must be the same as the treatment effect in those
initially randomised to the study drug, which is unlikely to be
true when the main cause for switching is disease progression.
Alternative methods for adjusting for treatment switching
(such as the inverse probability of censoring weights, IPCW,
method), as well as intention-to-treat analyses should be con-
ducted and presented. Soares et al. [54] have demonstrated
that these methodological choices can have a very significant
impact on cost-effectiveness estimates and therefore lead to
decision uncertainty.
Another problem encountered when comparing multiple
novel therapies is that there are frequently no head-to-head
comparisons of the treatments in randomised controlled trials.
Where trials have shared a common comparator (often place-
bo) indirect comparisons and multiple treatment comparisons
[13] can be appropriate under certain assumptions. One of the
assumptions is that treatment effect modifiers (patient charac-
teristics which affect the relative effectiveness of one or more
treatments, as opposed to simply being prognostic) are distrib-
uted equally across studies. This assumption can be relaxed by
using population-adjusted indirect comparisons when there is
access to individual patient data (IPD) in one of the studies in
the indirect comparison [48]. One such approach (matching
adjusted indirect comparison, MAIC) weights patients in the
trials where IPD are available to match the patient character-
istics in another trial before conducting an indirect
comparison.
If the aim is to compare across conditions, health-related
quality of life in a clinical setting can be measured using a
generic preference-based multi-attribute utility instrument,
such as the EQ-5D, and should be valued using an appropriate
tariff (e.g., from a time trade-off or standard gamble study).
However disease-specific instruments are often more sensitive
and responsive for certain health states [63]. Areas where in-
accuracy was introduced in the economic evaluations
Rev Endocr Metab Disord
reviewed included making certain assumptions without justi-
fication [55], using other disease areas as proxies [55], use of
vignette studies which value hypothetical disease states [27]
and referencing unpublished data [27].
Little is known about preference based values associated
with health related quality of life outcomes of targeted thera-
pies after disease progression. Almost all evidence originates
from randomised clinical trials whichmeasure these outcomes
at fixed time points driven by dosing schedules, which vary
across treatments, typically with high drop-out rates. This sug-
gests longitudinal preference based assessment of quality of
life outcomes of NEN, based on representative patient cohorts,
is needed. This evidence would help distinguish patient pref-
erences and relative effectiveness between targeted therapies
in advanced or metastatic pancreatic NETs which have similar
clinical outcomes but different safety profiles [41].
All the included studies were model-based economic eval-
uations rather than being economic evaluations alongside clin-
ical trials (EEACT). EEACT include direct measurements of
healthcare resource use, for example through resource use
questionnaires, claims and other databases and also measure-
ments of effectiveness, e.g. preference-based health-related
quality of life. Model-based economic evaluations can accu-
rately estimate costs in the delivery setting (although this is
dependent on having high quality data sources), but are less
likely to accurately estimate any knock-on effects on costs
[20]. In a single centre study the data collection for an
EEACT is typically not prohibitive, but for multi-centre (and
particularly multinational) trials, data may be more challeng-
ing to collect.
Where studies do not incorporate quality of life (i.e., by
using LYs instead of QALYs), decision-makers should be
aware that incremental QALYs can be considerably lower
than incremental LYs in economic evaluations of cancer treat-
ments unless substantial improvements to quality of life are
realised. This means ICERs with QALYs as denominators can
be much greater than ICERs with LYs as denominator. Soares
et al. [54] estimated an ICER of €24,000/LY, however the best
estimate of a cost-effectiveness threshold for Portugal is
€30,000/QALY. Assuming a fairly typical utility value of
0.7 this would lead to an estimated ICER of around
€34,000/QALY.
The limitations of the study mainly relate to the limitations
of our systematic review and also to the available evidence.
The search terms may not capture all available literature how-
ever to attempt to remedy this citation searching and ‘grey’
literature searches using google scholar were performed. We
did not look for articles outside of the English language which
meant at least one relevant economic evaluation in NEN was
not included which has appeared in a previous review [40].
Although EMBASE and other related databases were includ-
ed in the search, we did not have access to the DIMDI
Superbase, which was used in the Chau et al. [9] review. We
did not perform a formal risk of bias quality assessment, rank
evidence according to grade or examine publication bias.
Limited data on costs hampers adoption decisions regard-
ing targeted treatments. A salient example is the uncertainty in
the value for money of PRRT in progressive or metastatic
NET, for which there is strong evidence of clinical benefits
in terms of progression free survival, but no data on impact on
healthcare resource utilisation and costs [41]. Further research
could aim to enrich the evidence base on resource use and
costs of NEN using electronic medical records and registry
data. Studies using models such as that of Laudicella et al.
[32] may generate the required generalizable evidence to in-
form timely policy decision making.
We recommend that investigators for future trials in NEN
should ensure that key endpoints for economic evaluations
(progression-free survival and overall survival) are not con-
founded by crossover (treatment switching), or that if cross-
over is allowed then studies should make this clear before-
hand, and collect all necessary data to support methods for
adjusting for crossover with different underlying assumptions
(e.g., IPCW and RPSFT or iterative parameter estimation
methods). The results of each of these different methods
should be presented alongside intention-to-treat analyses.
Investigators should release anonymised patient-level data to
support more reliable syntheses of studies and ideally collect
preference-based health-related quality of life measures (e.g.,
EQ-5D) on a schedule which minimises bias (for example,
measurements should not be taken only prior to drug admin-
istration). We also suggest investigators conducting economic
evaluations should release their modelling as open data to
maximise transparency and further research in the field.
10 Conclusion
Overall we conclude that although there has been progress
since 2013 [9], there are still only a small number of high
quality independent economic evaluation studies in NEN.
Most HEEs do not meet published health economic criteria
used to assess quality. Clinicians should be cautious when
interpreting economic evaluations of high-cost treatments of
NEN given the complexities associated with comparisons
across heterogeneous trials with confounding of relevant out-
comes. Further research with high-quality effectiveness data
and rigorous applied health economic analysis is needed.
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Appendix 1: Search strategy
“((((exp “NEUROENDOCRINE TUMOR“/ OR (“neuroen-
docrine tumour“ OR “neuroendocrine tumor“).ti,ab OR exp
“GASTROENTEROPANCREATIC NEUROENDOCRINE
TUMOR”/ OR (“gastroenteropancreatic neuroendocrine
tumour“).ti,ab OR (“gastroenteropancreatic neuroendocrine
tumor“).ti,ab OR exp CARCINOID/ OR (“carcinoid tumor”
OR “carcinoid tumour”).ti,ab)
AND
(OCTREOTIDE/ OR ANGIOPEPTIN/ OR “ALPHA
INTERFERON”/ OR “ALPHA2B INTERFERON”/ OR
EVEROLIMUS/ OR RAPAMYCIN/ OR SUNITINIB/ OR
“LUTETIUM 177”/ OR (octreotide OR lanreotide OR
interferon-a OR interferon alpha-2b OR everolimus OR
s i r o l imu s OR sun i t i n i b OR 177Lu ) . t i , a b OR
CHEMOTHERAPY/ OR RADIOTHERAPY/ OR
“TUMOR ABLATION”/ OR RADIOEMBOLIZATION/
OR “ARTIFICIAL EMBOLIZATION”/ OR SURGERY/
OR (“trans arterial chemoembolization”).ti,ab OR
TELOTRISTAT/ OR (chemotherapy OR radiotherapy OR
ablation OR radioembolisation OR radioembolizationOR em-
bolization OR embolization OR surgery OR telotristat).ti,ab))
AND
(HOSPITALIZATION/ OR “HOSPITALIZATION
COSTS”/ OR (hospitalisation OR hospitalization).ti,ab OR
“COST OF ILLNESS”/ OR (“cost of illness”).ti,ab OR
MORTALITY/ OR (mortality).ti,ab OR “AMBULATORY
CARE”/ OR (“ambulatory care”).ti,ab OR (“work loss”).ti,ab
OR DISABILITY/ OR (disability).ti,ab OR “HEALTH
CARE COST”/ OR (“healthcare cost*”).ti,ab OR (“health
care cost*”).ti,ab OR (“treatment pattern*”).ti,ab OR
“DRUG UTILIZATION”/ OR (“drug utilisation” OR “drug
utilization”).ti,ab OR (“unmet needs”).ti,ab OR “QUALITY
OF LIFE”/ OR (“quality of life”).ti,ab OR (“health economic
analysis”).ti,ab OR “HEALTH ECONOMICS”/ OR
“HEALTH CARE UTILIZATION”/ OR (“resource
utilisation” OR “resource utilization”).ti,ab OR (“financial
toxicity” OR “cost-effectiveness” OR economics).ti,ab OR
(“cost of disease” OR “cost of sickness” OR “burden of dis-
ease” OR “burden of illness” OR “hospital cost” OR “cost of
medical care”OR “cost of drug*”OR “cost of healthcare”OR
“cost of health care” OR “cost of treatment” OR “treatment
cost”OR “illness cost”OR “health* cost”OR “drug cost”OR
“medical care cost” OR “sickness cost” OR “economic
burden”).ti,ab OR (“economic impact” OR “health services”
OR “drug prescriptions” OR “direct cost” OR “intangible
cost” OR “surg* cost” OR payment OR economic OR
pharmacoeconomic OR absenteeism OR “illness day” OR
“sick day”OR “sick leave”OR “work absen*”OR retirement
OR “work day loss” OR “work incapability” OR “work loss”
OR “work day loss” OR “work time loss” OR “working in-
capacity” OR “workers compensation”).ti,ab))
AND
((Registry OR registries).ti,ab OR REGISTER/ OR
“OBSERVATIONAL STUDY”/ OR (“observational
stud*”).ti,ab OR exp. REVIEW/ OR (review).ti,ab OR
“PRACTICE GUIDELINE”/ OR (guideline*).ti,ab OR
CONSENSUS/ OR (consensus).ti,ab OR (“meta-analysis”
OR “systematic review” OR survey*).ti,ab)) [DT 2010–
2019] [English language]”.
Appendix 2: Critical appraisal
Critical appraisal was conducted using the Philips checklist [47]
Author & Year S1 S2 S3 S4 S5 S6 S7 S8 S9 D1 D2a D2b D2c D3 D4a D4b D4c D4d C1 C2
Takemoto 2010 (abstract) [58] Y N N N N U Y Y U N U U NA N N N N N N N
Soares 2011 (abstract) [54] Y Y N N N U Y Y U N U U NA N Y N N N N N
Walczak 2012 (abstract) [61] Y Y N N N U Y U U N U U U N Y N N N N N
Marty 2012 [37] Y N N N Y Y N NA NA N Y Y NA Y N N N N N N
Johns 2012 (abstract) [26] Y Y N N N U U U U N U U U N U U N U N N
[28] (abstract) [28] Y Y N N N U Y Y U N U U U N N N N N N N
Casciano 2012 [7] Y Y N Y N N Y Y Y Y Y N N Y N N N Y N N
Spolverato 2015 [55] Y Y N Y N Y Y N Y N N N N Y N N Y Y Y N
Joish 2018 [27] Y Y N N Y Y Y Y Y N Y N N N N N N Y N N
Mujica-Mota 2018 [41] Y Y Y/N Y Y N Y Y Y Y Y U Y Y Y Y Y Y Y Y
Chua 2018 [10] Y Y N Y Y N Y Y Y N Y N Y Y Y Y N Y N N
Ray 2019 (abstract) [50] Y N N N U U U U NA N NA NA NA N N N N N N N
Key: Y Yes fulfils criteria, N No does not fulfil criteria, NA Not applicable
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